RAPID for Unresectable Colorectal Liver Metastases
NCT07919951, Not applicable, Not yet recruiting, Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Trial 10
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | RAPID for Unresectable Colorectal Liver Metastases | ClinicalTrials.gov |
| NCT number | NCT07919951 | ClinicalTrials.gov |
| Status | Not yet recruiting | ClinicalTrials.gov |
| Phases | Not applicable | ClinicalTrials.gov |
| Enrollment | 10 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | ClinicalTrials.gov |
| Conditions | Colorectal Liver Metastases (CRCLM), Colorectal Neoplasms | ClinicalTrials.gov |
| Interventions | RAPID Procedure | ClinicalTrials.gov |
| First posted | 2026-11-05 | ClinicalTrials.gov |
| Last updated | 2026-11-05 | ClinicalTrials.gov |
Registered outcomes 3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | 2-Year Tumor Event-Free Survival Rate | From Stage 1 surgery to tumor progression, recurrence, or death from any cause, assessed up to 2 years after Stage 1 surgery | Proportion of participants alive and free of tumor progression or recurrence at 2 years after Stage 1 surgery. A tumor event is defined as tumor progression or recurrence confirmed by imaging (CT/MRI/PET-CT) according to RECIST 1.1 or by pathology, or death from any cause, whichever occurs first. Participants who fail to complete Stage 2 surgery are counted as having an event from the date of Stage 2 failure, regardless of whether tumor progression has occurred. Participants last known to be alive and event-free are censored at the date of last follow-up. | ClinicalTrials.gov |
| Secondary | Incidence of Major Perioperative Complications (Clavien-Dindo Grade ≥IIIa) | From Stage 1 surgery through 90 days after Stage 2 surgery | Proportion of participants experiencing Clavien-Dindo grade ≥IIIa complications from Stage 1 surgery through 90 days after Stage 2 surgery. Grade IIIa indicates complications requiring surgical, endoscopic, or radiological intervention without general anesthesia; grade IIIb requires intervention under general anesthesia; grade IV indicates life-threatening organ dysfunction requiring ICU management; grade V indicates death. Complications are recorded by type (e.g., primary graft non-function, small-for-size syndrome, biliary complications, vascular complications, bleeding, infection, renal failure requiring replacement therapy, respiratory failure requiring mechanical ventilation). | ClinicalTrials.gov |
| Secondary | Stage 2 Completion Rate | From Stage 1 surgery until Stage 2 completion or up to Day 42 after Stage 1 surgery | Proportion of participants who successfully complete Stage 2 completion hepatectomy among all participants who undergo Stage 1 surgery. The decision to proceed to Stage 2 is made by the multidisciplinary team based on graft volume growth (target GRWR ≥0.8% or graft volume doubling) and recovery of liver function. Participants who do not proceed to Stage 2 by Day 42 after Stage 1, or who discontinue the surgical pathway due to tumor progression or persistent graft dysfunction, are counted as not completing Stage 2. | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 2
The papers the trial lists on ClinicalTrials.gov.
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)